Wills Hughes-Wilson

Wills is the Chief Patient Access and Commercial Planning since 2018. Prior to Mereo, she was Chief Patient Access Officer at Swedish Orphan Biovitrum (Sobi), where she led the company’s go-to-market commercialization approach and built the pricing, reimbursement and access teams.

Prior to Sobi, Wills was Vice President Health and Market Access Policy at Genzyme Corporation (acquired by Sanofi), securing in-market availability for the company’s orphan drug, rare disease and advanced therapies products portfolio. She has served as Industry Coordinator on the E.U. Commission’s Committee of Experts on Rare Diseases and Industry lead on the EMA’s Committee for Orphan Medicinal Products (COMP) Working Group with Interested Parties.

Wills holds a B.A. in Law and Politics from the University of Durham, U.K.